Pacific Biosciences Of California (PACB) Total Current Liabilities (2010 - 2026)

Pacific Biosciences Of California has reported Total Current Liabilities for 17 years, with the latest figure at $65.4 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities fell 1.87% year-over-year to $65.4 million; the trailing twelve-month figure through Mar 2026 stood at $65.4 million (down 1.87% YoY), and the FY2025 full-year result was $72.8 million, up 9.85% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $65.4 million, down from $72.8 million in the prior quarter.
• The five-year high for Total Current Liabilities was $271.4 million in Q2 2023, with the low at $59.8 million in Q2 2025.
• Average Total Current Liabilities over 5 years is $112.5 million, with a median of $73.0 million recorded in 2024.
• Year-over-year, Total Current Liabilities surged 335.46% in 2023 and slumped 72.54% in 2024.
• Tracing PACB's Total Current Liabilities over 5 years: stood at $263.3 million in 2022, then slumped by 63.91% to $95.0 million in 2023, then plunged by 30.23% to $66.3 million in 2024, then advanced by 9.85% to $72.8 million in 2025, then fell by 10.26% to $65.4 million in 2026.
• The last three Total Current Liabilities figures came in at $65.4 million (Q1 2026), $72.8 million (Q4 2025), and $63.2 million (Q3 2025), per Business Quant data.

Peer Comparison